Clinical Trial Update: Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line bortezomib plus cisplatin in malignant mesothelioma. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• CISPLATIN (cisplatin)
• Velcade (bortezomib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Malignant Mesothelioma | Phase 2 | Status: COMPLETED